Repare (NASDAQ: RPTX) shareholders approve acquisition by XenoTherapeutics

Repare Therapeutics Inc. (NASDAQ: RPTX) announced that shareholders approved the acquisition of the clinical-stage precision oncology company by XenoTherapeutics, Inc. and Xeno Acquisition Corp., a non-profit biotechnology company.

The special resolution approving the arrangement received support from 99.76% of votes cast by shareholders at a special meeting. Shareholders also approved executive compensation related to the transaction by 99.34% of votes cast.

The transaction remains subject to approval by the Superior Court of Québec and other customary closing conditions. The court hearing for final approval is scheduled for January 23, 2026, with the transaction expected to close on or about January 28, 2026.

Repare Therapeutics develops cancer therapies focused on genomic instability and DNA damage repair. The company’s clinical pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor.

XenoTherapeutics is a Massachusetts-based 501(c)(3) research foundation that focuses on advancing xenotransplantation through scientific research, clinical development, and public education.